Menu Display

Breadcrumb

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

Tue Oct 07 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Joins BioLabs San Diego as Platinum Sponsor Download
Mon Oct 06 00:00:00 GMT-05:00 2025 NEW
DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial Download
Thu Oct 02 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Establishes Third Research Institute in San Diego Download
Wed Oct 01 00:00:00 GMT-05:00 2025 NEW
ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery Download
Mon Sep 29 00:00:00 GMT-05:00 2025 NEW
ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Risk Early Breast Cancer Following Neoadjuvant Therapy Download
Wed Sep 24 00:00:00 GMT-05:00 2025 NEW
ENHERTU® Plus Pertuzumab Granted Priority Review in the US as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer Download
Mon Sep 15 00:00:00 GMT-05:00 2025 NEW
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab Download
Sun Sep 07 00:00:00 GMT-05:00 2025
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial Download
Wed Aug 27 00:00:00 GMT-05:00 2025
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy Download
Mon Aug 18 00:00:00 GMT-05:00 2025
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer Download
Page 1 of 21
10 Items per Page
Showing 1 - 10 of 207 results.